Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SMA
SMA
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
Wed, 09/4/24 - 10:49 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Spinal muscular atrophy market to reach $3bn across 7MM by 2033
Clinical Trials Arena
Wed, 07/17/24 - 09:12 pm
SMA
spinal muscular atrophy
Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children
PM Live
Fri, 06/14/24 - 11:38 am
Roche
SMA
Evrysdi
clinical trials
Roche’s Evrysdi offers sustained benefits in SMA extension trial in children
Clinical Trials Arena
Mon, 06/10/24 - 11:06 am
Roche
clinical trials
Evrysdi
SMA
Biogen, Delta soar together to improve air travel accessibility
Medical Marketing and Media
Thu, 06/6/24 - 09:09 pm
Biogen
philanthropy
SMA
mobility
Novartis reports data from Phase IIIb trial of SMA therapy
Clinical Trials Arena
Tue, 03/5/24 - 11:15 am
Novartis
SMA
clinical trials
Zolgensma
Novartis, Voyager launch another gene therapy mission with $100M upfront deal
Fierce Biotech
Tue, 01/2/24 - 10:05 am
Novartis
gene therapy
Voyager Therapeutics
Huntington's disease
SMA
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
BioSpace
Wed, 10/4/23 - 09:41 am
Roche
Genentech
clinical trials
Evrysdi
SMA
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
BioSpace
Mon, 07/3/23 - 11:38 am
Genentech
spinal muscular atrophy
SMA
Evrysdi
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Sun, 03/26/23 - 03:36 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Mon, 03/20/23 - 04:47 pm
Novartis
SMA
Zolgensma
gene therapy
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Tue, 01/17/23 - 10:26 am
Novartis
gene therapy
Zolgensma
SMA
Europe
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Tue, 01/10/23 - 10:55 am
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Tue, 10/25/22 - 11:02 pm
Novartis
gene therapy
spinal muscular atrophy
SMA
Zolgensma
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
BioSpace
Wed, 10/12/22 - 11:45 pm
Novartis
Zolgensma
data manipulation
SMA
Novartis reports deaths of two patients treated with Zolgensma gene therapy
BioPharma Dive
Thu, 08/11/22 - 11:32 pm
Novartis
gene therapy
Zolgensma
SMA
patient deaths
spinal muscular atrophy
Intercept, Annovis and Biohaven Advance Late Phase Trials
BioSpace
Mon, 07/11/22 - 12:00 am
Intercept Pharma NASH
Annovis
buntanetap
Parkinson's Disease
Biohaven
taldefgrobep alfa
SMA
Roche puts pressure on SMA rivals with new FDA approval
Pharmaforum
Tue, 05/31/22 - 10:33 am
Roche
PTC Therapeutics
SMA
Evrysdi
FDA
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
BioSpace
Fri, 04/29/22 - 10:30 am
Genentech
Evrysdi
risdiplam
SMA
spinal muscular atrophy
Pages
1
2
3
4
5
6
next ›
last »